EAST-ASIA PHARMACEUTICAL: Subsidiary obtains CNAS laboratory accreditation certificate

Zhitong
2025.07.04 08:15

EAST-ASIA PHARMACEUTICAL announced that its wholly-owned subsidiary Hangzhou Shanli Biomedical Technology Co., Ltd. recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment. The certificate is effective from May 20, 2025, and will expire on May 19, 2031. This accreditation signifies that the management level and technical capabilities of the Hangzhou Shanli analysis laboratory have received national and international recognition, demonstrating the ability to conduct testing according to national standards. This will help enhance the company's product quality, research and development capabilities, and customer trust, thereby strengthening overall competitiveness and promoting high-quality development. This accreditation will not have a significant impact on the company's current performance

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.